MELBOURNE, Australia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce a partnership with the Gold Coast Private Hospital (GCPH), a member of Healthscope, to establish a Precision Medicine Clinic at the hospital.
Highlights:
According to the US Food and Drug Administration (FDA), Precision Medicine, also known as "personalised medicine" is an innovative approach to tailoring disease prevention and treatment that takes into account differences in people's genes, environments, and lifestyles. The goal of precision medicine is to target the right treatments to the right patients at the right time. Utilising GTG’s geneType Multi-test and PGx tests will be an important step in improving health outcomes for GCPH’s patients.
Research Manager for the Gold Coast private hospital, Michelle Ferrari Cestari, commented, “We have a clear vision for a Precision Medicine Clinic that focuses on preventative care, wellness and creating proactive patient pathways that lead to early detection, and better treatment of the common diseases.”
Enquiries
Investor Relations
Adrian Mulcahy
Automic Markets
M: +61 438 630 411
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com
About Gold Coast Private Hospital by Healthscope
Gold Coast Private Hospital by Healthscope is a 336 bed and 22 theatre hospital is home to leading doctors and surgeons. The focus is on the patient with and expert team of surgeons, specialist doctors, dedicated nurses and other supporting health professionals ensuring holistic health care experience is the best it can be.
Offering the latest technology, and truly impressive state-of-the-art facilities, they attract leading doctors and surgeons from across the world. This, in turn, has meant that we are the Gold Coast hospital of choice for GPs, consultants and, of course, patients who quite rightly place a premium on their health and wellbeing https://goldcoastprivatehospital.com.au
Healthscope is Australia's only national private hospital operation and healthcare provider with a network of 42 hospitals that service every state and territory. With over 19,000 people and provide work for nearly as many accredited medical practitioners. Our people are known for achieving exceptional clinical outcomes, transparent public reporting and positive patient feedback that leads the industry. No matter the role, every day the people make a difference to the lives of patients, their families and carers, and it is a privilege to be part of their care. https://healthscope.com.au/
Last Trade: | US$0.78 |
Daily Volume: | 0 |
Market Cap: | US$3.780M |
August 15, 2024 May 29, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load